Circulating levels of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 diabetes
| Autor: | Jeyaratnaganthan, Nilani, Højlund, Kurt, Kroustrup, Jens Peter, Larsen, Jens Fromholt, Bjerre, Mette, Levin, Klavs, Beck-Nielsen, Henning, Frago, Susana, Hassan, A Bassim, Flyvbjerg, Allan, Frystyk, Jan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
Gastroplasty Endocrinology Diabetes and Metabolism medicine.medical_treatment Type 2 diabetes Validation Studies as Topic Receptor IGF Type 2 Cohort Studies Endocrinology Thinness Insulin-Like Growth Factor II Weight loss Diabetes mellitus Internal medicine Weight Loss medicine Extracellular Humans Nutritional Physiological Phenomena Obesity Receptor business.industry Insulin Case-control study medicine.disease Diabetes Mellitus Type 2 Case-Control Studies medicine.symptom business Blood Chemical Analysis |
| Zdroj: | Jeyaratnaganthan, N, Højlund, K, Kroustrup, J P, Larsen, J F, Bjerre, M, Levin, K, Beck-Nielsen, H, Frago, S, Hassan, A B, Flyvbjerg, A, Frystyk, J & Larsen, J F 2010, ' Circulating levels of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 diabetes ', Growth Hormone & IGF Research, vol. 20, no. 3, pp. 185-191 . https://doi.org/10.1016/j.ghir.2009.12.005 Jeyaratnaganthan, N, Højlund, K, Kroustrup, J P, Larsen, J F, Bjerre, M, Levin, K, Beck-Nielsen, H, Frago, S, Hassan, A B, Flyvbjerg, A & Frystyk, J 2010, ' Circulating levels of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 diabetes ', Growth Hormone & IGF Research, vol. 20, no. 3, pp. 185-91 . https://doi.org/10.1016/j.ghir.2009.12.005 |
| ISSN: | 1532-2238 1096-6374 |
| DOI: | 10.1016/j.ghir.2009.12.005 |
| Popis: | OBJECTIVE: The extracellular domain of the insulin-like growth factor II/mannose-6-phosphate receptor (IGF-II/M6P-R) is present in the circulation, but its relationship with plasma IGF-II is largely unknown. As IGF-II appears to be nutritionally regulated, we studied the impact of obesity, type 2 diabetes (T2D) and weight loss on circulating levels of IGF-II and its soluble receptor. METHODS: Twenty-three morbidly obese non-diabetic subjects were studied before and after gastric banding (GB), reducing their BMI from 59.3+/-1.8 to 52.7+/-1.6 kg/m(2). Lean controls (n=10, BMI 24.2+/-0.5 kg/m(2)), moderately obese controls (n=21, BMI 31.8+/-1.0 kg/m(2)) and obese T2D patients (n=20, BMI 32.3+/-0.8 kg/m(2)) were studied before and after a hyperinsulinaemic euglycaemic clamp. RESULTS: Morbidly obese subjects had elevated IGF-II/M6P-R and IGF-II levels, which both decreased following GB (IGF-II/M6P-R: from 0.97+/-0.038 to 0.87+/-0.030 nmol/l, P=0.001; IGF-II: from 134+/-7 to 125+/-6 nmol/l, P=0.01), as did fasting plasma glucose and insulin (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect